BioTime’s Subsidiary OncoCyte Corporation and The Wistar Institute To Collaboratively Develop Cancer Diagnostics

- PanC-DxTM Markers to be Tested in Multi-Center Lung Cancer Study Currently Underway -

BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte has entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to collaboratively develop lung cancer diagnostic products. As part of the collaboration, Wistar investigators are conducting a multi-center patient study in which they are assessing gene expression patterns in blood cells of patients with malignant versus non-malignant lung disease.

Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada

Commences Scientific Advice Working Party Process With EMA for Clarity on Path Forward for ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in Europe

Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the Company has completed patient enrollment in its Phase 2 clinical study of ARIKACE^®, or liposomal amikacin for inhalation, for patients with recalcitrant nontuberculous mycobacterial (NTM) lung disease in the U.S. and Canada. ARIKACE has received Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of NTM lung infections. 

FDA Agrees with Omeros' Pediatric Study Plan for OMS302

-- Completion of Pediatric Study Can Lead to Additional Marketing Exclusivity -

Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) confirmed its agreement with the Pediatric Study Plan (PSP) proposed by Omeros to study the use of OMS302 in pediatric patients undergoing primary cataract extraction. The FDA also issued a Written Request consistent with the PSP, which means that successful completion of the PSP would make OMS302 eligible for an additional six months of marketing exclusivity in the U.S. Added to standard irrigation solution used during ophthalmological procedures, OMS302 is Omeros' proprietary PharmacoSurgery^® product designed to maintain intraoperative mydriasis (pupil dilation), prevent surgically induced miosis (pupil constriction), and reduce postoperative pain resulting from cataract and other lens replacement surgery.

OncoMed Pharmaceuticals Receives First U.S. Patent on MAbTrap(TM) Antibody Display Technology

OncoMed Pharmaceuticals, Inc. (OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the United States Patent and Trademark Office has granted OncoMed its first U.S. patent on its MAbTrap(TM) antibody display technology, one of the company's novel antibody platform technologies. OncoMed's MAbTrap(TM) technology enables the rapid identification of monoclonal antibodies that bind a particular target or set of targets, and bind such target or targets with high affinity and specificity. OncoMed has used the patented technology to identify and/or optimize novel antibodies, including proprietary bispecific antibodies, and demonstrated the activity of these antibodies in preclinical studies.